-
ASCO Post: Brian I. Rini, MD, on Renal Cell Carcinoma: Results from the TIVO-3 Trial on Tivozanib vs Sorafenib (2019 Genitourinary Cancers Symposium; Feb. 14-16)
Watch the video »TIVO-3: A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib to Sorafenib in Subjects with Refractory Advanced Renal Cell Carcinoma
Download the presentation »
-
Latest Events
AVEO Oncology at 2019 Cantor Fitzgerald Global Healthcare Conference
Friday, October 4, 2019TIVO-3 OS Update Call
Tuesday, September 10, 20192019 BIO International Convention
Wednesday, June 5, 2019
